CSI Market
Sign In | Register

Adma Biologics Inc (ADMA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ADMA quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Adma Biologics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income146.93
Depreciation & amortization16.10
Amortization of Other Assets0.86
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories36.23
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.01
Share-based Compensation20.03
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-3.34
Stock Based Compensation-
Loss On Sale Of Inventory-
Debt Instrument Increase Accrued Interest-
Increase Decrease In Deposits And Other Assets-0.14
Amortization Of License Revenue-
Income taxes11.02
Gain on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable108.43
Increase (Decrease) in Accounts Payable0.71
Increase (Decrease) in Accrued Liabilities5.21
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-9.50
Other Working Capital-1.23
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-281.05
Discontinued operations0.00
Net Cash flow from Operating Activities50.40
Investing Activities
Capital Expenditures-22.89
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments0.00
Short-term Investments Acq.0.00
Payments for Leasing Costs0.00
Deposit Received On Net Assets Held For Sale-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net1.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-21.89
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-28.96
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-15.07
Debt Issuance Costs-
Payment Of Hercules End Of Term Fee-
Proceeds From Oxford Note Payable-
Prepayment Penalty Of Early Extinguishment Of Note Payable-
Payment Of Debt Refinancing Fees-0.45
Taxes Paid On Vested Restricted Stock Units-4.97
Finance Lease Principal Payments-
Payment Of End Of Term Fee-0.38
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-44.02
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow27.51
Total Cash Flow-15.52
4 historic quarters locked

Sign in to unlock the full Adma Biologics Inc cash flow history.

Sign In Create Free Account

About Adma Biologics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001140361-26-006815

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License